Personalized nutrition project seeks volunteers with Diabetes subject 2 to study blood sugar control with innovative postbiotic
DiabeT2Predict, a project funded by the State research Agency and the European Union-NextGenerationEU/PRTR, with 1.7 million euros to study the effectiveness of the postbiotic developed by the Navarra business Genbioma, integrating genetic factors and microbiota of each patient.
FotoManuelCastells
/Professor Pedro González, principal researcher of the study at the University of Navarra.
04 | 07 | 2025
The study is led by the biotechnology company Genbioma, specialized in the development of postbiotics to improve metabolic health, and its goal is to evaluate the effect of one of its postbiotic formulas on glycemic control and intestinal microbiota.
To this end, a multicenter nutritional intervention essay is being carried out, coordinated by the research center in Nutrition of the University of Navarra (CIN), which is being developed at the Clínica Universidad de Navarra (Pamplona and Madrid sites), the BioBizkaia Health research Institute and the CIN itself. This is an intervention in which recommendations can be personalized according to the Genetics and microbiota of each patient, with a focus on a precision nutrition approach .
In this phase, the Navarra center is looking for volunteers between 18 and 70 years old with subject 2 diabetes to participate in the study. Interested persons can contact via email voluntariosnut@unav.es or by calling 948 425 744.
"The goal is to apply supplementation with postbiotics developed by the project leader to address glycemic control, better understanding the particularities of each patient and adapting the treatment according to their Genetics and gut microbiota," says Pedro González Muniesa, principal researcher of the study at the University of Navarra. "This approach will allow us to offer solutions based on postbiotic supplementation as a novel strategy that is more effective and compatible with medication, and to contribute to reducing the health impact of subject 2 diabetes in Spain, which currently represents 9% of the total health expense ".
An innovative strategy for the management of subject 2 diabetes
As part of the study, it will be analyzed whether Genbioma's postbiotic formulation contributes to improve glycemic control and intestinal microbiota in a personalized way taking into account the genetic characteristics of each patient.
"The novelty of this study is that we do not intend to replace pharmacological treatment, but to provide each patient with all the information he or she needs, so that postbiotic supplementation is as effective as possible," explains González Muniesa. As a nutritional intervention in the form of a food supplement, this approach allows a more direct transfer of the laboratory to the patient and is expected to be safe and well tolerated, with no side effects or drug interactions expected.
